Hatch BioFund backs Princeton spinout Optimeos to crack drug delivery
What's the deal? Hatch BioFundDealroom has a profile for this one. Try Dealroom → has led an early-stage investment in Optimeos Life Sciences, a Princeton University spinout building a non-viral nanoparticle platform to deliver RNA, DNA and protein therapies. Financial terms were not disclosed.
Based in Princeton, New Jersey, Optimeos uses a patented process called Coated Inverse Nanocarriers (CINCs), refined over two decades in the lab of professor emeritus Robert Prud'homme.
The platform encapsulates therapeutic payloads with efficiencies above 90%, while supporting scalable manufacturing and customisable design.
Why now? Advances in RNA, DNA and protein therapies have accelerated, but delivering these molecules precisely to the right cells remains a core bottleneck.
Optimeos claims its technology offers modular tissue targeting, tunable immunogenicity and dosing flexibility — addressing limits of existing lipid nanoparticle systems.
Its pipeline includes a gene replacement therapy for the rare metabolic disorder citrullinemia type I, plus programs in T-cell engineering and targeted pulmonary therapies.
What could go wrong? The platform must move from academic research to clinical and commercial use, a leap that is far from guaranteed.
Optimeos is betting on being a delivery technology rather than a single drug, which spreads risk but also depends heavily on partnerships to prove value.
The signal: Hatch BioFund, an early-stage investment fund based at the Pennsylvania Biotechnology Center, continues to concentrate its bets on academic spinouts with platform potential — a thesis that hinges on delivery technology becoming as valuable as the therapies it carries.
Read more: citybiz
